Related Experiment Videos
Quantitative Metabolomics in Alzheimer's Disease: Technical Considerations for Improved Reproducibility
Sergio Veiga1, Judith Wahrheit2, Andrés Rodríguez-Martín3
1Biocross S.L., Boecillo (Valladolid), Spain. sveiga@biocross.es.
Methods in Molecular Biology (Clifton, N.J.)
|June 11, 2018
Summary
Metabolomics offers sensitive insights into physiological changes, aiding Alzheimer's disease (AD) diagnosis. However, challenges in replicating diagnostic algorithms highlight the need for standardized technical guidance in metabolomic data analysis.
Area of Science:
- Metabolomics and neurodegenerative disease research.
- Application of metabolomic analysis in diagnostics.
Background:
- Metabolomics provides a sensitive measure of physiological changes, making it valuable for studying complex diseases like Alzheimer's disease (AD).
- Existing metabolomic diagnostic algorithms for AD lack consistent replication across different cohorts, indicating methodological challenges.
Purpose of the Study:
- To provide technical guidance for applying quantitative metabolomic data to develop discriminative algorithms for neurodegenerative disease diagnosis, specifically AD.
- To highlight technical aspects that hinder replication of metabolomic studies, even with standardized assays.
Main Methods:
- Review of untargeted and targeted metabolomic approaches applied to AD.
- Discussion of the AbsoluteIDQ® p180 Kit as a standardized assay for metabolite measurement.
- Analysis of technical considerations from sample collection to data handling.
Main Results:
- Both untargeted and targeted metabolomics have yielded diagnostic algorithms for AD.
- The AbsoluteIDQ® p180 Kit standardizes metabolite measurement but has not fully resolved replication issues.
Conclusions:
- Standardized assays like the AbsoluteIDQ® p180 Kit are crucial but insufficient for ensuring replication of metabolomic diagnostic algorithms.
- Further technical standardization and methodological consensus are required to achieve reliable and reproducible metabolomic-based diagnosis for neurodegenerative diseases like AD.